Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2020-01-16 DOI:10.17650/1726-9776-2019-15-4-84-92

K. Nyushko, B. Alekseev, V. Krylov, A. Kaprin

{"title":"Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice","authors":"K. Nyushko, B. Alekseev, V. Krylov, A. Kaprin","doi":"10.17650/1726-9776-2019-15-4-84-92","DOIUrl":null,"url":null,"abstract":"Castration-resistant prostate cancer (CRPC) has a very negative prognosis. The average life expectancy even using modern treatment methods is 1.5–2 years. When the majority of CRPC patients show signs of resistance to therapy aimed at lowering testosterone levels, distant metastases are often determined in the bones. Bone metastases in CRPC patients often worsen life quality due to pain and risk of bone complications, such as pathological fractures and spinal cord compression. Not all treatment regimens to increase their life expectancy patients are effective. Radiopharmacy using alpha-emitting radium-223 chloride is not only one of the methods of palliative treatment, but also one of the most promising therapies that increase life expectancy of these heavy patients. Results of large randomized trials showed that alpha-therapy with radium-223 chloride leads to a significant increase of the overall life expectancy, and significantly improve the patients’ life quality. The article presents literature review as well as the analysis of the results of large randomized trials, which assess the effectiveness of the therapy in CGRG patients, and a clinical case of its use in real clinical practice.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"15 1","pages":"84-92"},"PeriodicalIF":0.1000,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2019-15-4-84-92","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Castration-resistant prostate cancer (CRPC) has a very negative prognosis. The average life expectancy even using modern treatment methods is 1.5–2 years. When the majority of CRPC patients show signs of resistance to therapy aimed at lowering testosterone levels, distant metastases are often determined in the bones. Bone metastases in CRPC patients often worsen life quality due to pain and risk of bone complications, such as pathological fractures and spinal cord compression. Not all treatment regimens to increase their life expectancy patients are effective. Radiopharmacy using alpha-emitting radium-223 chloride is not only one of the methods of palliative treatment, but also one of the most promising therapies that increase life expectancy of these heavy patients. Results of large randomized trials showed that alpha-therapy with radium-223 chloride leads to a significant increase of the overall life expectancy, and significantly improve the patients’ life quality. The article presents literature review as well as the analysis of the results of large randomized trials, which assess the effectiveness of the therapy in CGRG patients, and a clinical case of its use in real clinical practice.

查看原文本刊更多论文

使用223氯化镭治疗去势抵抗性前列腺癌患者。从临床研究到日常实践

去势抵抗性前列腺癌(CRPC)预后非常差。即使使用现代治疗方法，平均预期寿命也只有1.5-2年。当大多数CRPC患者对旨在降低睾酮水平的治疗表现出抵抗迹象时，远处转移通常确定在骨骼中。CRPC患者的骨转移通常会因疼痛和骨并发症(如病理性骨折和脊髓压迫)的风险而恶化生活质量。并不是所有提高患者预期寿命的治疗方案都有效。放射药理学使用放射-223氯化物不仅是姑息治疗的方法之一，而且是最有希望延长这些重患者预期寿命的治疗方法之一。大型随机试验结果显示，223氯化镭治疗可显著提高患者的总体预期寿命，显著改善患者的生活质量。本文通过文献综述和大型随机试验的结果分析，评估了该疗法在CGRG患者中的有效性，并结合实际临床应用了一个临床案例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.